Clearside Biomed Stock Price, News & Analysis

Clearside Biomedical (NASDAQ:CLSD) announced participation in three upcoming investor conferences in August 2022. The events include:

• BTIG Biotechnology Conference: Panel Discussion on August 9 at 10:00 am ET in New York City.
• Wedbush PacGrow Healthcare Virtual Conference: Fireside Chat on August 10 at 8:35 am ET.
• H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference: Panel and Corporate Presentation on August 17 at 11:00 am ET.

Links to live and archived webcasts are available on Clearside's website.

Clearside Biomedical (NASDAQ:CLSD) announced it will report its Q2 2022 financial results on August 9, 2022, before market opening. The company specializes in innovative therapies targeting the back of the eye via the suprachoroidal space. A webcast and conference call will be held at 8:30 a.m. ET to discuss the financial results and provide updates on corporate developments. Registration for the event is available on the Clearside website.

Clearside Biomedical has completed dosing in Cohorts 3 and 4 of its Phase 1/2a clinical trial, OASIS, for CLS-AX (axitinib injectable suspension) targeting neovascular age-related macular degeneration (wet AMD). The trial, which enrolled 27 patients, assesses safety and tolerability through suprachoroidal injection. Preliminary data is expected in Q4 2022. CLS-AX, a tyrosine kinase inhibitor, aims to offer better efficacy through broad VEGF blockade. The successful trial completion is seen as a critical milestone for Clearside's innovative drug delivery platform.

Clearside Biomedical (CLSD) announced multiple presentations at the ASRS Annual Meeting and OIS Retina Innovation Summit from July 13-16, 2022, in New York. These presentations will highlight the company’s suprachoroidal delivery platform, XIPERE, and SCS Microinjector technology. Notable discussions include a panel on drug delivery and key presentations on the efficacy of XIPERE for treating macular edema associated with uveitis. XIPERE was FDA-approved in October 2021 and is now commercially available in the U.S.

Clearside Biomedical (NASDAQ:CLSD) has appointed Susan L. Coultas, Ph.D., as its new Chief Clinical Officer. With over 35 years in clinical development, her experience includes senior roles at multiple ophthalmic companies. Dr. Coultas will oversee the planning and execution of Clearside's clinical trials, including the lead candidate, CLS-AX, aimed at treating neovascular age-related macular degeneration. The executive team, including Dr. Thomas Ciulla, will work closely with her to enhance the company’s clinical pipeline and operational effectiveness.

Clearside Biomedical, Inc. (Nasdaq: CLSD) will feature Chief Medical Officer Thomas A. Ciulla in a Fireside Chat at the JMP Securities Life Sciences Conference on June 15, 2022, at 9:30 a.m. ET in New York. This event emphasizes Clearside's innovative SCS injection platform, which enables non-surgical therapy delivery to the eye, targeting conditions that threaten vision. The live and archived webcast will be accessible via the Clearside website for three months. Clearside's first product, XIPERE, is an injectable suspension currently available in the U.S.

Clearside Biomedical (CLSD) announced the commercial launch of its first approved suprachoroidal product, XIPERE (triamcinolone acetonide injectable suspension), for treating macular edema associated with uveitis in the U.S. The company reported first-quarter 2022 revenue of $347,000, up from $34,000 in Q1 2021. Operating expenses decreased to $7.993 million from $8.383 million. However, the net loss slightly increased to $7.6 million with a loss per share of $0.13. The company maintains cash reserves of $34.4 million sufficient for its operations over the next twelve months.

Clearside Biomedical, Inc. (Nasdaq: CLSD) announced multiple presentations at the ARVO 2022 Annual Meeting showcasing its suprachoroidal delivery platform, XIPERE®, and SCS Microinjector®. Key findings indicated that the SCS Microinjector allowed targeted and durable delivery of small molecule suspensions, demonstrating potential for improved retinal therapies. XIPERE, approved by the FDA in 2021, is now commercially available for treating macular edema associated with uveitis. Dr. Thomas Ciulla will also participate in the Retina World Congress 2022 for further discussions on retinal diseases.

Clearside Biomedical (NASDAQ: CLSD) will report its Q1 2022 financial results on May 11, 2022, post-market close. Following the announcement, management will host a webcast at 4:30 p.m. ET for discussion and corporate updates. Clearside Biomedical focuses on delivering therapies to the back of the eye via its proprietary SCS Microinjector, aiming to enhance vision in patients with sight-threatening conditions. The company’s product, XIPERE, is already available in the U.S.